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As of June 2016 there are 28 medical schools [1] in 
both private and public sectors in Malaysia offering 
more than twice as many programs [2] with yearly 
graduates of about 4500 including those that graduated 
from overseas. This magnitude is beyond the usual 
capacity of Ministry of Health (MOH) that is entrusted 
to accord preregistration training posts to the graduates 
as the whole process of allocation to available places in 
public hospitals nationwide is painfully slow. It is 
already a tragedy having to wait 6 months on average 
for a placement but words that a delay for up to a year 
can occur is totally unacceptable when the actual 
training places available at grade DU41 preregistration 
house officers is said to be more than the graduate 
number [3]. Delay can be detrimental to the training 
itself because waiting is a waste of talent and potential, 
a disincentive to a young aspirant, tacitly is a testimony 
of system failure and deprives the public of highly 
trained graduates to serve in our healthcare system that 
ironically suffers from chronic and ever growing wait 
but yet we have excess medical graduates. Some of 
them have taken a simple and quick route out of the 
mess by migrating to our neighbours near and far, not 
entirely their faults, but their thresholds to despair seem 
very low indeed. The need for a speedy and right 
solution to the delay is long overdue and this is nothing 
more than what the public and the young doctors 
deserve. 
  How did we get to this? Not unexpectedly but 
the magnitude stemmed from the unusually large 
number of Sijil Pelajaran Malaysia (SPM; Malaysia 
Certificate of Education) leavers that opted to study 
medicine, in part made easy by the many medical 
schools in the country and those that have been 
accredited abroad. This was augmented by the constant 
reminder of the need for more doctors, parental or hype 
pressure perhaps for whatever reasons, and also the ease 
with which scholarships were available to study 
medicine. The principle driver for the whole mess was 
money initiated by those who wish to make profits 
under these “fortunate” circumstances [4]. The resulting 
deluge of medical graduates clogged the system up and 
unfortunately created many of the unnecessary 
challenges that we face today. Paradoxically despite 
this excess our doctor population ratio is still lower than 
the Organization for Economic Cooperation and 
Development (OECD) average and our more 
prosperous neighbour in the south. These veiled and 
unscrupulous drivers are addressing the gap in ratio 
with such a speed that it strains the system to almost 
breaking point and had somewhat ruffled both Ministry 
of Higher Education (MOHE) and MOH. 
  The doctor number that we need should ideally 
be planned or rather managed at this point and this can 
only be done by addressing all the factors that had led 
us to this. For a start we should look at the basic 
question of what the country needs in the future (2020 
and beyond) and then work backwards. This sounds 
simple enough but in practice this is where the 
challenge lies. Two ministries MOH and MOHE are 
both looking at the issue albeit with different focus but 
inevitably with some overlapping jurisdiction. The 
MOH concerns with the nation’s health issues and 
MOHE deals with medical education and consequently 
doctor number, although seemingly separate but in 
actual fact they will converge. Whatever the number of 
medical students approved at Malaysian Qualifications 
Agency (MQA) / Malaysian Medical Council (MMC) 
or sponsored by Jabatan Perkhidmatan Awan (JPA; 
Public Services Department) /MOHE the final tally in 
five years will be the medical graduates that will have 
to be allocated to training places. Too many medical 
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graduates too soon appear to be the main problem and 
therefore it is high time that we try to regulate the 
number that goes into training. Immediate actions are 
required too to restore public confidence in the light of 
unsympathetic media comments. This includes policies 
that require hard choices such as derecognizing some 
foreign medical schools in the archaic list of schedule 2 
and introducing the right to practice examination for 
those who have graduated from abroad. Both can 
regulate number and consequently emphasize quality. 
  The next challenge is the specialist number 
now that doctor number at lower grades will address the 
gap in ratio in time. Although a lot has improved but by 
most estimates the number of specialists must double to 
take up the challenges of a developed nation status and 
we need to add to this the question of disparity (uneven 
number by specialty) and geographical mal-distribution, 
unfortunately the issues remain despite numerous 
incentives introduced by MOH over the years. An 
easier question of churning up specialist number can be 
addressed rather immediately because we have a robust, 
economical, and internationally respected system within 
our midst that is the Master in Medicine (MMED). But 
when the issue of increasing the specialist number is 
debated, the discourse mystically takes a pathetic 
course to the times when postgraduate medicine began 
in the country in the 60s, a return to our colonial 
ancestry for training opportunities and supervision. 
When postgraduate medicine first started we indeed 
relied heavily on the hospitals in the United Kingdom 
(UK) and their college exams but these are things of the 
past. Except for stated and specific niche areas for 
training and education, or occasional exception, by and 
large we have existed and trained our specialist 
independently from the system in the UK for more than 
three decades. For the record, to date more than 8000 
specialists have graduated from MMED system and for 
a rapidly growing Malaysia this number is huge. 
Especially so for the surgical based specialties that are 
the most challenging to train and in all domains the 
surgeons have been at par with the very best in the 
world. In fact from our own survey, MMED trained 
specialists are the backbone of doctors that service the 
public hospitals and clinics in Malaysia. 
 
  Despite this apparent regression, the 
universities that offer MMED are in the process of 
institutionalizing the training pathway and system to 
maintain the quality and improve the process further. 
Steps are taken to formalize the training pathway via 
MQA and MOHE to reinforce public perception of the 
system and in preparation for soon to be implemented 
trade and economic liberalization in ASEAN. For 
practical purposes the MMED system essentially has 
two types; one that is based on the presence of the 
faculty’s own teaching hospital and the other on the 
absence of one and thus reliance on the state hospital as 
the faculty’s affiliated teaching hospital. Both models 
have achieved success and maintained the quality and 
competency required by a robust comprehensive 
assessment system that includes standardized 
examinations attended by a wide selection of examiners 
in the country and abroad. In the next 5 years or so, the 
training environment to some extent the MMED will 
undergo a significant change with the completion of 
another 7 teaching hospitals and the incorporation of a 
consortium of university teaching hospitals. With an 
estimated number of nearly 10000 tertiary care beds at 
peak activity this will provide an excellent opportunity 
to train more specialists and partake in subspecialty 
training. This includes research and teaching activities 
that will enhance the return on investment to the public. 
  Based on the cumulative years of experience 
and a much more organized MQA the future of medical 
education for both undergraduate and postgraduate 
looks very promising indeed but the main lingering 
issues in both must be addressed. For undergraduate 
medicine the need to maintain a robust and stringent 
control on quality is paramount and data shows that the 
emphasis of this is mainly on graduates from some 
foreign medical schools because the local ones are 
subject to very stringent accreditation exercise and 
compliance audit, therefore quality is assured. Another 
strategy to achieve this is the introduction of fitness to 
practice examination for foreign medical school 
graduates. Both will help control number. The main 
issue that is affecting postgraduate education is the need 
to institutionalize the MMED for the future and the 
creation of teaching hospitals consortium by working 
closely with MQA and MOHE. This will ensure the 
best deal for the public. The future is in our hands. 
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INTRODUCTION 
Depression is a normal response to loss or misfortune 
and such response may be called grief or mourning. 
However, depression is abnormal when it is out of 
proportion to the misfortunes or is unduly prolonged 
[1]. Depression can occur in any psychiatric disorder. 
The symptoms of depressed mood are component of 
many psychiatric syndromes and are also commonly 
detected in certain physical diseases [1, 2]. In general, 
the prevalence of depression for women ranges from 5-
12%, while among men it ranges from 2-3% [3]. 
Scientists believe that depression has a biochemical 
basis. It reflects the neurotransmitter and hormonal 
imbalances that affect the brain functions. Researchers 
have detected decreased levels of serotonin and 
dopamine in the brain of people who have chronic or 
severe depression [4]. 
 Prostate cancer is the second most common 
cancer in men with an incidence 25.3 per 100,000 
worldwide and the second leading cause of cancer-
related death in man [5-7]. The incidence of prostate 
cancer is rising steadily with a global estimate of 3% 
increase every year [8]. It was estimated that 217,730 
men will be diagnosed with and 32,050 men will die of 
prostate cancer in the year 2011 [9]. In developed part 
of the world, prostate cancer accounts for 9.7% percent 
of cancer in men whereas in underdeveloped world it 
accounts for only 4.3% [10].
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 Prostate cancer patients experience greater 
incidence of clinically significant depression than men 
without prostate cancer [11, 12]. Additionally, men with 
prostate cancer have higher rates of depression 
compared to men in the general population [13]. Study 
by Walker J et al., [14] reported that the prevalence of 
depression among prostate cancer patients was 8.2% 
which was lower compared to depression among 
psychiatric outpatients (24%) [15] and patients who 
attended general practice [18.5% (95% CI: 16.5 – 20.6)] 
[16]. 
 Prostate cancer patients have been reported to 
experience depression while undergoing treatment. 
Among those who were treated with radiotherapy, 27% 
suffered with significant levels of depression [13] and 
those who had orchidectomy had a slightly higher risk 
for depressive disorder (RR = 1.15; 95% CI, 1.03 – 
1.27) [17]. The risk for depressive disorders was 1.13% 
(95% CI: 1.08 – 1.19) among prostate cancer patients 
who received androgen deprivation compared to 
patients without cancer [17]. However, hormonal 
therapy does not appear to cause significant depression 
among men with locally advanced prostate cancer. The 
rate of mild depression was found to vary from 10.4-
16.3% over a period of 12 months with no significant 
differences at different time points [18]. 
 In early prostate cancer, the assessment of 
health related quality of life (HRQOL) is mostly 
evaluated with regards to the degree of urinary 
incontinence, sexual impotence after treatment and 
patients’ satisfaction with the outcome [19-23]. The 
clinicians and patients must consider the impact on 
quality of life (QOL) when choosing primary therapy 
since the complications such as sexual, urinary and 
bowel dysfunction are likely in localized prostate 
cancer [24]. Many studies have revealed that 
symptomatic advanced prostate cancer has significant 
impact on QOL [22]. Men with advanced prostate 
cancer are typically treated with hormone therapy along 
with chemotherapy and/or radiotherapy to alleviate pain 
due to bony metastases [25]. Being married, having 
better education and being more affluent tends to slow 
the rate of decline in the physical domain of HRQOL 
[26]. The clinicians’ estimate of QOL impairment was 
found to be accurate for more than 60% of patients. 
Spiritual well-being (SWB) was shown to have a strong 
relationship with QOL but was not associated with the 
overall accuracy of clinicians’ judgment in advanced 
cancer patients [27]. 
 Many studies have been done to estimate the 
QOL and depression among prostate cancer patients. 
However, studies have not been done to determine 
prevalence of depression and its relationship with 
HRQOL among prostate cancer patients and to 
determine the factors contributing to the difference in 
the QOL between the two depression status groups. 
Therefore, this study was conducted to determine the 
prevalence of depression and its relationship with 
HRQOL among prostate cancer patients at tertiary 
centres in Kuala Lumpur. 
 
METHODS 
Study Design 
It was a hospital-based, cross-sectional study involving 
prostate cancer patients attending surgical clinics at 
University Malaya Medical Centre (UMMC) and 
Universiti Kebangsaan Malaysia Medical Centre 
(UKMMC), Kuala Lumpur. 
 
Selection of the Patient 
All patients aged 50 years and above with diagnosis of 
prostate cancer were invited to participate in the study. 
The patients were chosen arbitrarily by using 
convenience sampling. The patients who came from 1st 
August 2011 to 30th September 2012 were invited to 
participate in the study. We excluded those who could 
not read and write Malay or English languages, patients 
with psychiatric problem and those with ongoing 
treatment for psychological problem. 
 
Method of Data Collection 
Three methods of data collection used in this study 
included: face to face interview using self-structured 
questionnaire, review of medical record and self-
administered questionnaire. Face to face interview 
using self-structured questionnaire was administered to 
collect primary data on the socio-demography, past 
medical and surgical history and sign and symptoms 
related to urination. Face to face interview enabled the 
investigator to clarify the questions, clarify the 
inconsistent answer from the participants and reduce 
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information bias by the participants. Patient’s medical 
records were reviewed to countercheck the information 
given by the participants and to obtain information on 
the past medical and surgical illness, drug histories and 
cancer status of the patients. Self-administered 
questionnaire was administered to assess the HRQOL 
and depression. 
 
Assessment of Health-Related Quality of Life 
(HRQOL) 
 
The HRQOL was assessed using Short Form Health 
Survey with 36-items (SF-36). SF-36 is a generic 
measure of health status as opposed to one that targets a 
specific age, disease or treatment [28] and it is a 
practical and valid instrument for use among older 
people [29]. The SF-36 comprises 36 items including 
eight domains targeting Physical Component Summary 
(PCS) and Mental Component Summary (MCS) which 
are suitable to measure the impact of intervention [30]. 
The eight domains are: Physical function (PF); role 
physical (RP); bodily pain (BP); mental health (MH); 
role-emotional (RE); vitality energy; general health 
perception (GH) and social functioning (SF). Physical 
function, role physical and bodily pains domains 
include questions that are strongly correlated to PCS 
such as those about physical health and possible 
limitations due to physical health. Whereas, mental 
health, role emotional and social functions are strongly 
correlated with MCS. Vitality and social function 
domains correlate significantly with both summaries 
and include questions about the feelings and possible 
limitations due to emotional problems [31]. 
 Each of the eight domains scored from 0 to 100 
with higher score indicating higher function [32]. The 
SF-36 has been shown to be reliable and valid [33]. The 
English version of SF-36 has been translated to Malay 
language by a group of researchers from University of 
Science, Malaysia (USM) under the International QOL 
Assessment (IQOLA) Project [34]. 
 
Assessment for Depression Score 
Depression score was assessed using Depression 
Anxiety Stress Scale Version-21 (DASS-21) [35]. 
DASS-21 comprises twenty-one items that are divided 
into three sub-scales that measure depression, anxiety 
and stress. There are seven items for depression (DASS-
Depression), seven items for anxiety (DASS-Anxiety) 
and seven items for stress (DASS-Stress). The DASS-
Depression assesses the dysphoria, hopelessness, 
devaluation of life, self-deprecation, anhedonia, inertia 
and lack of interest [35]. The items were ranked on a 4-
point Likert scale, and assessed stressful experiences 
over previous one week. The responses ranged from 0 
(did not apply to me at all) to 3 (applied to me very 
much, or most of the time). The individual items were 
summed and timed twice to get the final total stress 
score, with higher scores indicating greater stress level. 
The depression was classified depending on the score of 
DASS-Depression (35): (i) 0 – 9: Normal; (ii) 10 – 13: 
mild depression; (iii) 14 – 20: moderate depression; (iv) 
21 – 27: severe depression; and (v) ≥ 28: very severe 
depression. 
 The original DASS-Depression, DASS-
Anxiety and DASS-Stress subscales have Cronbach’s 
alpha ranging from 0.76 to 0.84 and the internal 
consistency ranging from 0.83 to 0.91 [35]. The Malay 
language translation of DASS-21 have demonstrated 
good concurrent and criterion-related validity [36]. The 
Cronbach’s alpha for Malay version of DASS-
Depression was 0.84. DASS-21 has been used to 
measure the dimension of depression, anxiety and stress 
among clinical sample [37] and non-clinical sample 
[38]. 
 
Statistical Analysis 
The data was analysed using Statistical Package for 
Social Science (SPSS) version 20.0 (SPSS Inc, 
Chicago, IL). The scoring for the QOL was performed 
using Microsoft Excel, Quality Metric SF-HRQOL 
scoring software (Quality Metric Incorporated, Lincoln, 
RI). The score of depression and total QOL were 
entered as continuous variables. The prevalence of 
depression was calculated after binary classification of 
the score of depression (depression and no depression). 
All independent variables were entered as categorical. 
 The hypothesis testing in this study was to 
determine whether there was any difference in the mean 
of total HRQOL between depression status adjusted 
groups with reference to other independent variables. 
The association between independent variables, the 
depression status (yes and no) and the score of QOL was 
analyzed by using two-way analysis of variance 
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(ANOVA). Results that showed statistical significance 
were re-analyzed using multi-factorial ANOVA to 
control for the confounding factors. After developing 
model, checking for the interaction and model 
assumption were done for the final model to find the 
factors that associated with the differences in QOL 
between two depression status groups among prostate 
cancer patients. 
 
RESULTS 
A total of 193 patients with prostate cancer were 
recruited during the study period. The response rate was 
93.4%. The internal consistency of the items in the 
DASS-Depression and SF-36 QOL were determined 
using Cronbach’s α. The highest score for depression 
was 26 and the lowest score for stress was 0. The 
highest score of HRQOL was 98.13 and the lowest 
score was 30.00. The Cronbach’s α for DASS-
Depression was 0.761 and for SF-36 QOL was 0.718. 
Table 1 shows the patient’s socio-demographics, 
medical and surgical characteristics and current prostate 
cancer status. 
 The prevalence of depression was 11.9% (95% 
CI: 7.0 – 17.0). There were 170 (88.1%) patients 
without any depression; 13 (6.7%) were having mild 
depression; 9 (4.7%) having moderate depression and 
one (0.5%) was having severe depression. There was no 
patient with very severe depression 
 Table 2 shows the distribution of the scores of 
all the domains of the HRQOL, two summary statuses 
and total QOL stratified by depression status. All the 
domain scores of the non-depression group were higher 
compared to depression group. In depression group, the 
highest score domain was mental health and the lowest 
score domain was role physical (72.87 and 22.83 
respectively). In non-stress group as well the highest 
score domain was mental health and the lowest score 
domain was role physical (83.81 and 62.35 
respectively). For the PCS, MCS and total QOL, the 
non-depression group scores were higher compared to 
depression group (69.41 vs 49.68, 75.40 vs 61.29 and 
72.30 vs 54.11, respectively). 
 
Table 1 Patient’s socio-demographics, medical and surgical characteristics 
and current prostate cancer status 
Patients’ characteristics Number of  patients 
(N = 193), n (%) 
a) Patients’ socio-demographics 
Age < 60 
60-69.9 
70-79.9 
> 80 
10 (5.2) 
54 (28.0) 
99 (51.3) 
30 (15.5) 
Race Malay 
Chinese 
Indian & Sikh 
60 (31.1) 
101 (52.3) 
28 (16.6) 
Marital status Married 
Not married 
Widow 
172 (89.1) 
5 (2.6) 
16 (8.3) 
Number of children < 5 
> 5 
120 (62.2) 
73 (37.8) 
Living condition Alone 
With partner / family 
11 (5.7) 
182 (94.3) 
Educational level Tertiary 
Secondary 
Primary 
73 (37.8) 
109 (56.5) 
11 (5.7) 
Smoking status Never smoke 
Ever smoke 
83 (43.0) 
110 (57.0) 
Consuming alcohol Never drinker 
Ever drinker 
139 (72.0) 
54 (28.0) 
   
b) Patients’ medical & surgical characteristics 
Comorbidities Yes 
No 
168 (87.0) 
25 (13.0) 
History of surgery Yes 
No 
119 (63.0) 
74 (37.0) 
Medical conditions Hypertension 
Hyperlipidemia 
Diabetes mellitus 
Heart disease 
Gout / Joint problem 
Asthma 
114 (67.9) 
65 (38.7) 
56 (33.3) 
58 (34.5) 
28 (16.7) 
12 (7.1) 
   
c) Current prostate cancer status 
Life in cancer < 5 years 
> 5 years 
142 (73.5) 
51 (26.4) 
Presenting PSA < 100 ng/ml 
> 100 ng/ml 
135 (73.8) 
48 (26.2) 
Type of cancer Adenocarcinoma 193 (100.0) 
Gleason score < 7 
7 
> 7 
85 (44.0) 
55 (28.5) 
53 (27.5) 
Latest PSA < 4 ng/ml 
> 4 ng/ml 
114 (59.1) 
79 (40.9) 
Metastases Yes 
No 
113 (58.5) 
80 (41.5) 
Treatment Active Surveillance 
Orchidectomy 
Radical 
prostatectomy 
Radiotherapy 
Tablet Casodex 
Injection Lucrine 
Injection Zoladex 
19 (9.8) 
29 (15.0) 
21 (10.9) 
 
60 (31.1) 
51 (26.4) 
52 (26.9) 
86 (44.6) 
Family history of 
prostate cancer 
Yes 
No 
51 (26.4) 
142 (73.6) 
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Table 2 The distribution of the scores of all the domains of the HRQOL, two summary statuses and total QOL by depression status 
 Depression (n = 23) [Mean (SD)] Non-Depression (n = 170) [Mean (SD)] 
Physical Functioning 43.48 (29.48) 73.91 (17.80) 
Role limitations due to physical health 22.83 (31.00) 62.35 (38.10) 
Bodily pain 55.04 (17.05) 69.00 (13.61) 
General health perception 65.52 (12.91) 75.08 (13.70) 
Vitality 55.22 (12.29) 70.97 (11.77) 
Physical Functioning 43.48 (29.48) 73.91 (17.80) 
Role limitations due to physical health 22.83 (31.00) 62.35 (38.10) 
Bodily pain 55.04 (17.05) 69.00 (13.61) 
General health perception 65.52 (12.91) 75.08 (13.70) 
Vitality 55.22 (12.29) 70.97 (11.77) 
Physical Coefficient Summary (PCS) 49.68 (14.31) 69.41 (14.16) 
Mental Coefficient Summary (MCS) 61.29 (14.39) 75.40 (11.88) 
Total Quality of Life (QOL) 54.11 (14.59) 72.30 (13.38) 
 
Table 3 shows the comparison of the scores of the 
domains of the HRQOL and two coefficient summaries 
among prostate cancer patients with different 
depression status. There were statistically significant 
differences in all domains of the QOL, PCS, MCS and 
the total QOL. This indicates that the overall QOL in 
the depression group was significantly lower compared 
to that in non-depression group of prostate cancer 
patients [mean difference: -18.19 (95% CI: -24.12, -
12.26), p < 0.001].
Table 3 The comparison of the scores of the domains of the health related quality of life and two coefficient summaries comparing the depression status among 
prostate cancer patients 
Domain Depression (n = 23) 
[Mean (SD)] / 
[Median (IQR)] # 
No Depression (n = 170) 
[Mean (SD)] / 
[Median (IQR)] # 
Mean Difference 
(95% CI) / Z δ 
p-value 
Bodily Pain 55.04 ± 17.05 69.00 ± 13.61 -13.96 (-20.11, -7.80) < 0.001* 
General health 65.52 ± 12.91 75.08 ± 13.70 -9.55 (-15.52, -3.59) 0.002* 
Vitality 55.22 ± 12.29 70.97 ± 11.77 -15.75 (-20.94, -10.59) < 0.001* 
Social Functioning 59.78 ± 14.57 73.68 ± 16.15 -13.89 (-20.90, -6.89) < 0.001* 
Mental Health 72.87 ± 15.35 83.81 ± 11.83 -10.94 (-16.33, -5.56) < 0.001* 
Role Emotional 66.67 (100.00) # 100.00 (33.33) # -3.102 δ 0.002* 
Physical Functioning 45.00 (60.00) # 80.00 (25.00) # -4.714 δ < 0.001* 
Role Physical 0.00 (50.00) # 75.00 (75.00) # -4.418 δ < 0.001* 
Physical Coefficient Summary 49.68 ± 14.31 69.41 ± 14.16 -19.73 (-25.94, -13.52) < 0.001* 
Mental Coefficient Summary  61.29 ± 14.39 75.40 ± 11.88 -14.15 (-19.49, -8.80) < 0.001* 
Total QOL 54.11 ± 14.59 72.30 ± 13.39 -18.19 (-24.12, -12.26) < 0.001* 
CI: confidence intervals; IQR: interquartile range; SD: standard deviation 
Z: Mann Whitney U test 
 *  denotes statistically significant at α = 0.05 
 
 
Two-way ANOVA analysis for the association 
between independent variables, the depression status 
(yes and no) and the QOL score showed many factors 
of significance. These factors included: (i) patients’ 
characteristics: age (p = 0.003), race (p = 0.016), 
religious (p = 0.019) and smoking status (p = 0.044); (ii) 
patients’ past medical and surgical illness: history of 
surgery (any type of surgery besides the surgery that 
was part of the treatment of prostate cancer) (p = 0.007); 
(iii) current urinary problems: frequency (p < 0.001), 
urgency (p = 0.007), nocturia (p = 0.001), satisfaction 
with the micturition (p < 0.001), intermittency (p < 
0.001), dysuria (p = 0.006), hematuria (p < 0.001) and 
incomplete emptying (p = 0.006); (iv) current cancer 
status: presenting PSA (p = 0.001) and latest PSA level 
(p = 0.024); and (v) treatment: orchidectomy (p = 
0.009). 
Table 4 shows the factors that influenced the 
QOL after adjustment using multifactorial ANOVA. 
The only three factors that had statistically significance 
included: age (p = 0.012), hematuria (p = 0.009) and 
history of orchidectomy (p = 0.023). The adjusted QOL 
for depression group was 55.71 (95% CI: 49.64, 61.78) 
and for the non-depression group was 67.79 (95% CI: 
63.09, 72.48). There was significant difference between 
these two group [F (df): 19.266 (1,165), p < 0.001].  
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Table 4 The factors that influenced the quality of life 
Variable Categories Adjusted QOL score (95% CI) Adjusted Mean Difference (95% CI) F stat (df) p-value 
Age category Less than 60 years old 
60 - 69.9 years old 
70 - 79.9 years old 
more than 80 years old 
70.40 (62.03, 78.77) 
61.03 (55.71, 66.34) 
58.44 (53.42, 63.46) 
57.13 (51.60, 62.66) 
reference 
-9.38 (-19.99, 1.24) 
-11.96 (-22.34, -1.58) 
-13.27 (-24.83, -1.72) 
3.736 (3,177) 0.012* 
      
Hematuria Yes 
No 
57.88 (51.62, 64.14) 
65.62 (60.97, 70.27) 
-7.74 (-13.52, -1.97) 
reference 
6.992 (1,177) 0.009* 
      
Orchidectomy Yes 
No 
58.90 (52.84, 64.96) 
64.60 (60.19, 69.00) 
-5.70 (-10.60, -0.80) 
reference 
5.260 (1,177) 0.023* 
*  denotes statistically significant at α = 0.05; R2 = 0.447 (Adjusted R2 = 0.400) 
 
 
DISCUSSION 
The prevalence of depression among prostate cancer in 
this study was relatively low [11.9% (95% CI: 7.0 – 
17.0)]. The prevalence found in our study was higher 
compared to that reported by Walker et al., [14] in 
Scotland (8.2%) but was lower compared to that 
reported by Nelson et al., (14 percent) [39], Sharpley & 
Christie (16 percent) [40] and Driksen et al. (51 percent) 
[41]. The differences in the findings among studies 
could be due to use of different questionnaire during 
assessment and differences in the study design. The 
prevalence of depression in this study was also lower 
compared to depression among patients with other 
clinical conditions such as psychiatric outpatients (24.0 
percent) [15], patients who attended to general practice 
(95% CI: 16.5 – 20.6) (18.5 percent) [16] and other 
cancer patients [3]. However, men with prostate cancer 
were shown to have higher rates of depression than men 
in the general population [13]. One of the studies 
showed that, clinically, depression among prostate 
cancer patients reduced from 24% to 12.5% from the 
time of diagnosis to the time of survey.  It was 
associated with reduction in psychomotor symptoms, 
agitation, weakness, fatigue and pessimism [42], 
However, Nelson et al. [43], found a consistent upward 
trend in mean depression score of a cohort over 5 years. 
 In this study, overall QOL among depression 
group was significantly lower compared to non-
depression group [mean difference: -18.19 (95% CI: -
24.12, -12.26), p < 0.001]. Prostate cancer patients with 
psychological distress were reported to have 
significantly worse social and emotional functioning 
[44]. Depressed mood has been associated with 
significantly decreased scores in all domains of 
HRQOL [45]. Chronic diseases also have negative 
effects on HRQOL [46]. Driksen et al., [41] concluded 
that the higher percentage of depression among prostate 
cancer was due to impact of the treatment received on 
the sleep performance as a side effect. In another study, 
those with highest risk for depression reported greater 
prostate cancer symptoms and side effect of the 
treatment [47]. Aass et al., [48] reported that depression 
was significantly correlated with impaired social life, 
professional work and previous psychiatric problems. 
They also found that depression increases in the 
presence of distant metastases, relapse or disease 
progression. Mental health condition was also 
responsible for significantly greater impairment in 
HRQOL [46] and men with advanced disease were 
significantly depressed than those with early stage 
disease [41]. It could be due to more invasive treatment 
and relatively poor prognosis [44]. 
 In our study, age was also found to affect QOL 
differently based on the depression status [F (df): 
3.3736 (3,177), p = 0.012]. Among the older patients, 
the HRQOL score was significantly different between 
two groups with different depression status. There was 
a slow decline in QOL with time among prostate cancer 
patients due to duration of illness and psychiatric 
difficulties [49]. Therefore, greater efforts are needed to 
understand the rehabilitation problems early in 
diagnosis and treatment and to accordingly target 
interventions with the aim of reducing later sequelae 
[49]. However, study by Nelson et al., [43] found that 
the aging was positively correlated with emotional QOL 
(r = 0.16). 
 Hematuria is not common in prostate cancer. 
However, advanced prostate cancer may present with 
haematuria [50]. Hematuria was found in 21.9% of the 
patients with cancer. In this study, hematuria 
significantly affected the QOL score among patients 
stratified by their depression status. It could be due to 
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the patients’ perception that the treatment was less 
effective and they may die sooner. Study by Panson et 
al., [22] found that hematuria was associated with lower 
QOL among prostate cancer patients and pre-diagnosis, 
the QOL in patients with hematuria was comparable 
between patients with bladder cancer and those with 
other cancers including prostate cancer [51]. 
 In this study, orchidectomy influenced QOL 
score of prostate cancer patients stratified by depression 
statuses. It could be due to feeling of hopelessness and 
difficulties in concentrating or maintaining the daily 
activities [52]. However, the study by Lucas et al., [53] 
showed that orchidectomy did not appear to affect QOL. 
 There were few limitations in our study. Since 
this was a cross-sectional study, it could not infer the 
temporal sequence [54] among the depression status, 
multiple associated factors and the QOL. Although this 
study found age, hematuria and orchidectomy as the 
important factors that affect HRQOL differently among 
the patients with difference in depression status, there 
was no strong evidence for the causality. An elaborate 
longitudinal study should be carried out to find the 
actual associated factors that can affect HRQOL. 
However, the findings of this study can be generalized 
to the population with prostate cancer since the sample 
size was relatively large. 
 Furthermore, convenience sampling used in 
this study has a tendency to non-sampling error like 
selection bias, response bias and non-response bias 
[55]. Selection bias is the major issue in this sampling 
method. Patients can easily hide the truth due to precise 
wording of questions; interviewer attitude and 
juxtaposition of one question with another which are 
typical sources of response bias. Therefore, a well-
designed probability sampling could minimize the 
selection bias. 
 SF-36 [56] and DASS-21 [35] questionnaires 
are self-administered. Sometimes SF-36 produces 
different results from those of the primary efficacy 
outcome and should be utilized more systematically 
[57]. In this study, reliability analysis was conducted to 
test the internal consistency of the answers and 
Cronbach’s α was 0.718 for SF-36 and 0.761 for DASS-
Depression. Hence, both questionnaires were good for 
psychometric assessment in this population and there 
was no issue of unreliability. 
Recommendations 
In future, clinicians should be trained by professionals 
to assess the depressive symptoms of their patients and 
to pay more attention on patients’ emotional concerns. 
Treating the urination and related problem by urologist 
may improve the QOL among prostate cancer patients 
with depression. 
 
CONCLUSIONS 
The prevalence of depression among prostate cancer 
patient was relatively low. There was a significant 
difference in the QOL among prostate cancer patients 
with difference in the depression status. Patients 
without depression had relatively higher QOL 
compared to patients with depression. Both physical 
and mental coefficient summaries were also lower 
among prostate cancer patients with depression. 
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